

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/009869 A1

(51) International Patent Classification⁷: **A61K 39/39**,
A61P 31/00

(21) International Application Number: PCT/IB02/03495

(22) International Filing Date: 26 July 2002 (26.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0118249.2 26 July 2001 (26.07.2001) GB
PCT/IB02/03191 20 June 2002 (20.06.2002) IB

(71) Applicant (*for all designated States except US*): **CHIRON SPA** [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CONTORNI, Mario** [IT/IT]; Chiron Spa, Via Fiorentina, 1, I-53100 Siena (IT). **MAFFEI, Massimo** [IT/IT]; Chiron Spa, Via Fiorentina, 1, I-53100 Siena (IT).


(74) Agents: **MARSHALL, Cameron, John** et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINES COMPRISING ALUMINIUM ADJUVANTS AND HISTIDINE



(57) Abstract: To improve the stability of vaccines comprising aluminium salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can be reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminium salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from *N. meningitidis*.



WO 03/009869 A1

VACCINES COMPRISING ALUMINIUM ADJUVANTS AND HISTIDINE

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

This invention is in the field of vaccine formulation.

5 BACKGROUND ART

As well as containing antigenic substances, vaccines contain substances such as diluents, excipients, preservatives, stabilisers and buffers. Typically, vaccines also contain adjuvants *i.e.* a substance which improves the immune response raised in response to the vaccine antigen.

10 The adjuvants traditionally used in human vaccines have been aluminium salts such as aluminium hydroxide and aluminium phosphate. Many other experimental adjuvants are known and these are reviewed in, for instance, reference 1. Adsorption to aluminium salts remains, however, the most common vaccine adjuvant formulation.

15 Although their use is widespread, aluminium salts may not always be compatible with particular antigens. It has been suggested, for instance, that aluminium hydroxide may not be suitable for use in multivalent vaccines including hepatitis B virus surface antigen [2] or for use with the capsular polysaccharide from *Haemophilus influenzae* [3]. It has also been suggested that different antigens within the same vaccine formulation should be adsorbed to different aluminium salts [4] for compatibility reasons.

20 As well as antigen compatibility, it is necessary to consider vaccine stability when using aluminium salts. For instance, their capacity for protein adsorption has been shown to drop over time at room temperature [5] and in response to autoclaving [6]. Alum salts may also cause difficulties in freeze drying [7]. Furthermore, it has been found that aluminium hydroxide can hydrolyse saccharide antigens [8], even at low temperatures and when the antigen is conjugated to a carrier protein, thus leading to reduced efficacy.

25 In general, these issues only arise when attention moves to formulating an antigen for clinical use and may not be appreciated during initial research and development of the antigen itself.

It is an object of the invention to provide improvements in the stability of vaccines which include aluminium salts and, in particular, improvements in pH stability (buffering) and adjuvant adsorption at various temperatures and/or improvements in antigen stability (*e.g.* reduction in hydrolysis).

30 DISCLOSURE OF THE INVENTION

The invention is based on the surprising discovery that the amino acid histidine enhances the stability of vaccines which include aluminium salt adjuvants. This has been found both for saccharide antigens and for protein antigens.

-2-

The invention thus provides a composition comprising an antigen, an aluminium salt and histidine. The invention also provides a process for producing this composition, comprising the step of admixing an antigen, an aluminium salt and histidine.

The antigen

5 The antigen is preferably a protein antigen or a saccharide antigen (optionally conjugated). Preferred antigens are from bacteria, with the bacterial genus *Neisseria* (e.g. *N.meningitidis*) being particularly preferred.

Specific bacterial antigens for use with the invention include:

- 10 – a protein antigen from *N.meningitidis* serogroup B, such as those in refs. 9 to 15, with protein '287' (see below) and derivatives (e.g. 'ΔG287') being particularly preferred,
- an outer-membrane vesicle (OMV) preparation from *N.meningitidis* serogroup B, such as those disclosed in refs. 16, 17, 18, 19 etc.
- a saccharide antigen from *N.meningitidis* serogroup A, C, W135 and/or Y, such as the oligosaccharide disclosed in ref. 20 from serogroup C [see also ref. 21].
- 15 – a saccharide antigen from *Streptococcus pneumoniae* [e.g. 22, 23, 24].
- an antigen from *Bordetella pertussis*, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B.pertussis*, optionally also in combination with pertactin and/or agglutinogens 2 and 3 [e.g. refs. 25 & 26].
- a diphtheria antigen, such as a diphtheria toxoid [e.g. chapter 3 of ref. 27] e.g. the CRM₁₉₇ mutant [e.g. 28].
- 20 – a tetanus antigen, such as a tetanus toxoid [e.g. chapter 4 of ref. 27].
- a protein antigen from *Helicobacter pylori* such as CagA [e.g. 29], VacA [e.g. 29], NAP [e.g. 30], HopX [e.g. 31], HopY [e.g. 31] and/or urease.
- a saccharide antigen from *Haemophilus influenzae* B [e.g. 21], preferably oligosaccharide.
- 25 – an antigen from *N.gonorrhoeae* [e.g. 9, 10, 11].
- an antigen from *Chlamydia pneumoniae* [e.g. 32, 33, 34, 35, 36, 37, 38].
- an antigen from *Chlamydia trachomatis* [e.g. 39].
- an antigen from *Porphyromonas gingivalis* [e.g. 40].
- an antigen from *Moraxella catarrhalis* [e.g. 41].
- 30 – an antigen from *Streptococcus agalactiae* (group B streptococcus) [e.g. 42, 43].
- an antigen from *Streptococcus pyogenes* (group A streptococcus) [e.g. 43, 44, 45].
- an antigen from *Staphylococcus aureus* [e.g. 46].
- an antigen from *Bacillus anthracis* [e.g. 47, 48, 49].

Specific viral antigens for use with the invention include:

- 35 – an antigen from hepatitis A virus, such as inactivated virus [e.g. 50, 51].

-3-

- an antigen from hepatitis B virus, such as the surface and/or core antigens [*e.g.* 51, 52].
- an antigen from hepatitis C virus [*e.g.* 53].
- polio antigen(s) [*e.g.* 54, 55] such as IPV.
- rabies antigen(s) [*e.g.* 56] such as lyophilised inactivated virus [*e.g.* 57, RabAvert™].
- 5 – measles, mumps and/or rubella antigens [*e.g.* chapters 9, 10 & 11 of ref. 27].
- influenza antigen(s) [*e.g.* chapter 19 of ref. 27], such as the haemagglutinin and/or neuraminidase surface proteins.
- an antigen from a virus in the flaviviridae family (genus flavivirus), such as from yellow fever virus, Japanese encephalitis virus, four serotypes of Dengue viruses, tick-borne encephalitis virus, West Nile virus.
- 10 – a pestivirus antigen, such as from classical porcine fever virus, bovine viral diarrhoea virus, and/or border disease virus.
- a parvovirus antigen *e.g.* from parvovirus B19.

The composition may comprise one or more of these bacterial and viral antigens. The composition may comprise no viral antigens.

Other antigens which may be used include:

- a prion protein (*e.g.* the CJD prion protein)
 - an amyloid protein, such as a beta peptide [58]
 - a cancer antigen, such as those listed in Table 1 of ref. 59 or in tables 3 & 4 of ref. 60.
- 20 Where a saccharide or carbohydrate antigen is used, it is preferably conjugated to a carrier protein in order to enhance immunogenicity [*e.g.* refs. 61 to 70]. Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria or tetanus toxoids. The CRM₁₉₇ diphtheria toxoid is particularly preferred. Other suitable carrier proteins include the *N.meningitidis* outer membrane protein [*e.g.* ref. 71], synthetic peptides [*e.g.* 72, 73], heat shock proteins [*e.g.* 74], pertussis proteins [*e.g.* 75, 76],
- 25 protein D from *H.influenzae* [*e.g.* 77], toxin A or B from *C.difficile* [*e.g.* 78], *etc.* Where a mixture comprises capsular saccharides from both serogroups A and C, it is preferred that the ratio (w/w) of MenA saccharide:MenC saccharide is greater than 1 (*e.g.* 2:1, 3:1, 4:1, 5:1, 10:1 or higher). Saccharides from different serogroups of *N.meningitidis* may be conjugated to the same or different carrier proteins.
- 30 Any suitable conjugation reaction can be used, with any suitable linker where necessary.

Toxic protein antigens may be detoxified where necessary (*e.g.* detoxification of pertussis toxin by chemical and/or genetic means [26]).

Human papilloma virus (HPV) virus-like particles (VLPs) are not preferred antigens (*cf.* WO00/45841, WO00/57906, WO01/28585).

-4-

Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens. Whole cell pertussis antigen may be used.

- 5 Antigen is preferably adsorbed to the aluminium salt.

Where HBsAg is present, preferably it is either adsorbed to aluminium hydroxyphosphate or is not adsorbed to any salt. Adsorption of HBsAg to an aluminium hydroxide is preferably avoided.

- 10 Where a *H.influenzae* saccharide antigen is present, preferably it is either adsorbed to aluminium hydroxyphosphate or is not adsorbed to any salt. Adsorption of Hib saccharides to an aluminium hydroxide is preferably avoided.

Antigens in the composition will typically be present at a concentration of at least 1µg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.

- 15 As an alternative to using proteins antigens in the composition of the invention, nucleic acid encoding the antigen may be used [*e.g.* refs. 79 to 87]. Protein components of the compositions of the invention may thus be replaced by nucleic acid (preferably DNA *e.g.* in the form of a plasmid) that encodes the protein.

The aluminium salt

- 20 The aluminium salt is preferably an aluminium hydroxide (*e.g.* aluminium oxyhydroxide) or an aluminium phosphate (*e.g.* aluminium hydroxyphosphate or orthophosphate), but any other suitable salt may also be used (*e.g.* sulphate *etc.* [*e.g.* see chapters 8 & 9 of ref. 1]). The salt may take any suitable form (*e.g.* gel, crystalline, amorphous *etc.*). Preferred salts are (amorphous) hydroxyphosphates and (crystalline) oxyhydroxide (boehmite).

- 25 Hydroxyphosphates are obtained by precipitation and the reaction conditions and reactant concentrations during the precipitation reaction influence the degree of substitution of phosphate for hydroxyl in the salt. Hydroxyphosphates generally have a PO₄/Al molar ratio between 0.3 and 0.99, and preferred salts have a ratio between 0.8 and 0.95 (*e.g.* 0.88±0.05). Hydroxyphosphates [Al(OH)_x(PO₄)_y, wherein the sum of the valence of each anion times its mole fraction is -3] can be distinguished from AlPO₄ by the presence of hydroxyl groups. For example, an IR spectrum band at 30 3146cm⁻¹ (*e.g.* when heated to 200°C) indicates the presence of structural hydroxyls.

Aluminium oxyhydroxide [AlO(OH)] can be distinguished from Al(OH)₃ by IR spectroscopy, in particular by the presence of an adsorption band at 1070cm⁻¹ and a strong shoulder at 3090-3100cm⁻¹,

- 35 Mixtures of different aluminium salts may also be used. It is preferred, however, to use essentially a single salt *e.g.* where two salts are used, the ratio of one to the other is at least 5:1 by weight *e.g.* at least 10:1, 100:1, 1000:1 *etc.*

The salt will generally be present such that the concentration of Al^{3+} is at least $1\mu g/ml$ (e.g. at least $10\mu g/ml$, at least $100\mu g/ml$ etc.).

The use of histidine in combination with an aluminium phosphate (particularly a hydroxyphosphate) is particularly advantageous for acidic antigens.

5 *The histidine*

Histidine is a standard amino acid and is readily available for use with the invention. As it is inherently biocompatible, it is safe, and thus advantageous as an component in vaccines.

10 The concentration of histidine in the composition will typically be at least $1\mu M$ and at most $1M$. The concentration is preferably at least $1mM$ (e.g. at least $2mM$, $3mM$, $4mM$, $5mM$ etc.) and is preferably at most $250mM$ (e.g. at most $200mM$, $150mM$, $100mM$, $90mM$, $80mM$, $70mM$, $60mM$, $50mM$, $40mM$, $30mM$, $20mM$, $10mM$ etc.). More preferably the concentration of histidine in the composition is between $2mM$ and $10mM$ (e.g. between $5mM$ and $8mM$) and, most preferably, it is about $5mM$.

The histidine is preferably L-histidine.

15 The histidine preferably acts as a buffer. Histidine buffers are well known to the skilled person. Accordingly, the histidine may be ionised within the composition of the invention.

The composition preferably has enhanced pH stability and/or reduced antigen hydrolysis when compared to an equivalent composition in which histidine buffer system is either replaced with a sodium phosphate buffer system or in which no buffer system is included. Reduced hydrolysis may
20 be a consequence of enhanced pH stability.

Histidine may be added to the composition in the form of the amino acid itself or in the form of a salt. A typical histidine salt is the monohydrochloride monohydrate.

It will be appreciated that references to histidine in the compositions of the invention refers to 'free' histidine rather than to any histidine residues which may be part of a polypeptide (e.g. the antigen)
25 within the composition.

Further characteristics of the composition

The composition is preferably in liquid form, but it may be lyophilised (cf. WO01/41800).

30 The composition may also comprise a sodium salt e.g. sodium phosphate or sodium chloride. The concentration of the sodium salt is preferably at least $1mM$ (e.g. at least $2mM$, $3mM$, $4mM$, $5mM$ etc.) and is preferably at most $10mM$ (e.g. at most $10mM$, $9mM$, $8mM$, $7mM$ etc.). More preferably the concentration of sodium salt in the composition is between $1mM$ and $5mM$ (e.g. between $2mM$ and $3mM$) and, most preferably, it is about $2.5mM$.

A particular advantage of the invention is that it allows good control of pH and adsorption in vaccines which contain high concentrations of free phosphate ions, which ions may be unavoidable
35 in the vaccine e.g. due to exchange with phosphates in the adjuvant, or due to residual phosphate

buffer. Where residual phosphate ions are present at between 3 and 5 mM, for example, pH is difficult to control between 6.0 and 7.0, and some antigens tend to desorb from adjuvants, but the addition of 5 to 10 mM histidine pH and adsorption to be controlled, including during storage at elevated temperatures.

- 5 The molar ratio of histidine to free phosphate is preferably at least 1.25:1 *e.g.* 1.5:1, 1.75:1, 2:1, 2.25:1, 2.5:1, 3:1, 4:1 *etc.*

The pH of the composition is preferably between 6 and 7 (*e.g.* between 6.3 and 7.0). The pH may be maintained by the use of a buffer. This will typically be achieved inherently by the histidine in the composition.

- 10 The composition will not, in general, contain: serum (*e.g.* fetal calf serum *etc.*) or other such components used in cell culture; host cell DNA at a level of greater than 100pg/dose for antigens purified from cell culture; living cells.

The composition will generally be sterile and/or pyrogen-free.

- 15 The composition may comprise a detergent (*e.g.* a Tween, such as Tween 80) in order to minimise adsorption of antigens to containers.

The composition preferably does not comprise a preservative. Where a preservative is present, mercurial preservatives (*e.g.* thimerosal) may be used (*cf.* WO98/34594). Preservatives which may be present or absent are 2-phenoxy-ethanol, methyl parabens, propyl parabens and benzyl alcohol (or mixtures thereof).

20 ***Immunogenic compositions and medicaments***

The composition of the invention is typically a vaccine composition.

The invention also provides a composition of the invention for use as a medicament. The medicament is preferably able to raise an immune response in a mammal against the antigen (*i.e.* it is an immunogenic composition) and is more preferably a vaccine.

- 25 The invention also provides the use of a composition of the invention in the manufacture of a medicament for raising an immune response in a mammal against the antigen. The medicament is preferably a vaccine.

- The invention also provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention. The immune response is preferably protective. The method may raise a booster response.

- 30 The mammal is preferably a human, and most preferably a child.

- These uses and methods are preferably for the prevention and/or treatment of a disease caused by a *Neisseria* (*e.g.* meningitis, septicaemia; gonorrhoea *etc.*), by *H.influenzae* (*e.g.* otitis media, bronchitis, pneumonia, cellulitis, pericarditis, meningitis *etc.*) or by pneumococcus (*e.g.* meningitis, sepsis, pneumonia *etc.*). The prevention and/or treatment of bacterial meningitis is thus preferred.

Vaccines according to the invention may either be prophylactic (*i.e.* to prevent infection) or therapeutic (*i.e.* to treat disease after infection), but will typically be prophylactic.

Further components of the composition

5 The composition of the invention will typically, in addition to the components mentioned above, comprise one or more 'pharmaceutically acceptable carriers', which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, trehalose (WO00/56365) and lipid aggregates (such as oil droplets or liposomes). Such carriers are
10 well known to those of ordinary skill in the art. The vaccines may also contain diluents, such as water, saline, glycerol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. A thorough discussion of pharmaceutically acceptable excipients is available in *Remington's Pharmaceutical Sciences* [*e.g.* ref. 88].

15 Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen, as well as any other of the above-mentioned components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (*e.g.* non-human primate, primate, *etc.*), the capacity of the
20 individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Dosage treatment may be a single dose schedule or a multiple dose schedule (*e.g.* including booster doses). The vaccine may be administered in conjunction with other
25 immunoregulatory agents.

The vaccine may be administered in conjunction with other immunoregulatory agents.

The vaccine may include an adjuvant in addition to the aluminium salt. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides
30 (see below) or bacterial cell wall components), such as for example (a) MF59™ (WO90/14837; Chapter 10 in ref. 1), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and
35 (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (2) saponin adjuvants, such as QS21 or Stimulon™ (Cambridge

Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMS may be devoid of additional detergent *e.g.* WO00/07621; (3) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), *etc.*),
 5 interferons (*e.g.* gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), *etc.*; (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) *e.g.* GB-2220221, EP-A-0689454; (6) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions *e.g.* EP-A-0835318, EP-A-0735898, EP-A-0761231; (7) oligonucleotides comprising CpG motifs [Krieg *Vaccine* 2000, 19, 618-622; Krieg *Curr opin Mol Ther* 2001 3:15-24; Roman *et al.*, *Nat.*
 10 *Med.*, 1997, 3, 849-854; Weiner *et al.*, *PNAS USA*, 1997, 94, 10833-10837; Davis *et al.*, *J. Immunol.*, 1998, 160, 870-876; Chu *et al.*, *J. Exp. Med.*, 1997, 186, 1623-1631; Lipford *et al.*, *Eur. J. Immunol.*, 1997, 27, 2340-2344; Moldoveanu *et al.*, *Vaccine*, 1988, 16, 1216-1224, Krieg *et al.*, *Nature*, 1995, 374, 546-549; Klinman *et al.*, *PNAS USA*, 1996, 93, 2879-2883; Ballas *et al.*, *J. Immunol.*, 1996, 157, 1840-1845; Cowdery *et al.*, *J. Immunol.*, 1996, 156, 4570-4575; Halpern *et al.*, *Cell. Immunol.*, 1996, 167, 72-
 15 78; Yamamoto *et al.*, *Jpn. J. Cancer Res.*, 1988, 79, 866-873; Stacey *et al.*, *J. Immunol.*, 1996, 157, 2116-2122; Messina *et al.*, *J. Immunol.*, 1991, 147, 1759-1764; Yi *et al.*, *J. Immunol.*, 1996, 157, 4918-4925; Yi *et al.*, *J. Immunol.*, 1996, 157, 5394-5402; Yi *et al.*, *J. Immunol.*, 1998, 160, 4755-4761; and Yi *et al.*, *J. Immunol.*, 1998, 160, 5898-5906; International patent applications WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581] *i.e.* containing at least one
 20 CG dinucleotide, with 5-methylcytosine optionally being used in place of cytosine; (8) a polyoxyethylene ether or a polyoxyethylene ester *e.g.* WO99/52549; (9) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (*e.g.* WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (*e.g.* WO01/21152); (10) an immunostimulatory oligonucleotide (*e.g.* a CpG
 25 oligonucleotide) and a saponin *e.g.* WO00/62800; (11) an immunostimulant and a particle of metal salt *e.g.* WO00/23105; (12) a saponin and an oil-in-water emulsion *e.g.* WO99/11241; (13) a saponin (*e.g.* QS21) + 3dMPL + IL-12 (optionally + a sterol) *e.g.* WO98/57659; (14) chitosan; (15) cholera toxin or *E.coli* heat labile toxin, or detoxified mutants thereof [89]; (16) microparticles of poly(α -hydroxy)acids, such as PLG; (17) other substances that act as immunostimulating agents to enhance
 30 the efficacy of the composition.

Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), *etc.*

Once formulated, the compositions of the invention can be administered directly to the subject. The
 35 subjects to be treated can be animals; in particular, human subjects can be treated. The vaccines are particularly useful for vaccinating children and teenagers.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for

enhanced adjuvant effect. Direct delivery of the compositions will generally be parenteral (*e.g.* by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue). The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (*e.g.* see WO98/20734), needles, and hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule (*e.g.* including booster doses).

The step of admixing antigen, aluminium salt and histidine

To make compositions of the invention, antigen, aluminium salt and histidine must be combined. It is preferred that, when the antigen and aluminium salt are mixed, the histidine should be present. Histidine is thus present during adsorption to the aluminium salt. This compares with adding histidine to an antigen/aluminium salt combination which already exists *i.e.* the histidine in the process is not simply added as a buffer after antigen and aluminium salt have interacted, but instead it is present during their interaction.

In the process of the invention, therefore, antigen is preferably admixed with a histidine/aluminium salt mixture. The process of the invention may therefore comprise the following steps: (a) preparing a mixture of the aluminium salt and the histidine; and (b) admixing the antigen with said mixture. The mixture of (a) is preferably aqueous and may be prepared in aqueous conditions or may be a dried mixture which is re-hydrated prior to use.

Once one or more antigens has been adsorbed to an aluminium salt in the presence of histidine, the mixture may be combined with other antigens *e.g.* combined with existing diphtheria, tetanus, pertussis, polio or hepatitis B virus compositions.

Definitions

The term “comprising” means “including” as well as “consisting” *e.g.* a composition “comprising” X may consist exclusively of X or may include something additional *e.g.* X + Y.

The term “about” in relation to a numerical value *x* means, for example, $x \pm 10\%$.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows SDS-PAGE analysis of antigenic compositions following centrifugation. Lane 1 includes MW markers (220, 97, 66, 46, 30, 21, 14 kDa). OMV antigen (2µg) was used in lane 2; ΔG287 antigen was used in lanes 3 (10µg) and 4 (0.5µg). The antigen used in lanes 5 and 6 was a combination of OMV (50µg/ml) and ΔG287 (100µg/ml) with 1mg/ml aluminium oxyhydroxide; the lane 5 composition included 10mM sodium phosphate (PBS), whereas the lane 6 composition included 5mM histidine in saline solution.

Figure 2 also shows SDS-PAGE analysis of antigenic compositions following centrifugation. Lane 1 includes the same MW markers as Figure 1. OMV antigen (2.5µg) was used in lane 2; ΔG287 antigen was used in lanes 3 (2µg) and 4 (0.5µg). The antigen used in lanes 5, 6 and 7 was a combination of OMV (50µg/ml) and ΔG287 (100µg/ml) with 1mg/ml aluminium oxyhydroxide in

saline solution (pH 6.5); the lane 5 composition included 2.5mM sodium phosphate, the lane 6 composition included 5mM histidine, and the lane 7 composition included 10mM histidine.

Figure 3 also shows SDS-PAGE analysis of antigenic compositions following centrifugation. Lane 1 includes the same MW markers as Figure 1. OMV antigen (2µg) was used in lane 2; ΔG287 antigen was used in lanes 3 (2µg) and 4 (0.5µg). The antigen used in lanes 5 and 6 was a combination of OMV (50µg/ml) and ΔG287 (100µg/ml) with 3.3mg/ml aluminium oxyhydroxide in saline solution (pH 6.5); the lane 5 composition included 2.5mM sodium phosphate (PBS), whereas the lane 6 composition included 5mM histidine in saline solution.

Figure 4 shows the pH stability of vaccine formulations at 4°C. Filled symbols represent vaccines buffered with 5mM histidine; open symbols represent vaccines buffered with 2.5mM sodium phosphate. The initial pH was 6.0 (diamond), 6.5 (square) or 7.0 (triangle). Figure 5 shows the same at 37°C.

Figure 6 shows a SDS-PAGE gel for various antigens. Lane 1 contains MW markers. Lanes 2 to 6 contain markers: (2) ΔG287-953; (3) 961c; (4) 936-741; (5) New Zealand OMVs; and (6) Norwegian OMVs. Lanes 7 to 10 show supernatants of centrifuged histidine formulations of the invention after 1 month storage at 2-8°C: (7) ΔG287-953; (8) 961c + 936-741 + ΔG287-953; (9) 961c + 936-741 + ΔG287-953 + OMV_{NZ}; (10) 961c + 936-741 + ΔG287-953 + OMV_{Norway}.

Figure 7 shows the same as Figure 6, but lanes 7-10 are after storage at 36-38°C.

Figure 8 shows a SDS-PAGE gel for various antigens. Lane 1 contains MW markers. Lanes 2 to 5 contain markers: (2) 961c; (3) 936-741; (4) New Zealand OMVs; and (5) Norwegian OMVs. Lanes 6 to 9 show supernatants of centrifuged histidine formulations of the invention after 1 month storage at 2-8°C: (6) 961c; (7) 936-741; (8) OMV_{NZ}; (9) OMV_{Norway}.

Figure 9 shows the same as Figure 8, but lanes 6-9 are after storage at 36-38°C.

Figure 10 shows a SDS-PAGE gel for New Zealand OMVs. Lane 1 contains MW markers. Lanes 2, 3, 6 & 7 contain OMV markers stored at either 2-8°C (lanes 2 & 3) or 36-38°C (lanes 6 & 7), present at either 2µg (lanes 2 & 6) or 1µg (lanes 3 & 7). Lanes 4, 5, 8 & 9 show OMVs in histidine formulations of the invention after 30 days storage at either 2-8°C (lanes 4 & 5) or 36-38°C (lanes 8 & 9). Lanes 4 & 8 show supernatant of centrifuged OMVs, whereas lanes 5 & 9 show pellets.

MODES FOR CARRYING OUT THE INVENTION

Example 1 – pH stability and adsorption of meningococcal B '287' antigen

Reference 11 discloses a protein antigen named '287' from *N.meningitidis* serogroup B. Reference 90 discloses a form of this antigen ('ΔG287') which is truncated to remove the N-terminal amino acids up to and including its hexaglycine region. 287 and ΔG287 are both able to elicit a protective immune response in mice. References 16 to 19 disclose OMV antigens from *N.meningitidis* serogroup B. These OMVs are also able to elicit a protective immune response in mice.

These two antigens were formulated by adsorption to aluminium oxyhydroxide adjuvant. Two adjuvant concentrations (1 mg/ml and 3.3 mg/ml) were tested.

Immunisation studies in mice showed that vaccine immunogenicity is linked to the level of adsorption of the antigens to the adjuvant. To assess adsorption levels, samples of the final formulations were centrifuged at 1300 rpm for 10 minutes and the supernatant was analysed by SDS-PAGE in order to detect the presence of non-adsorbed antigen. The relevant protein standards at an appropriate concentration were loaded adjacent for quantitative comparison.

In order to maintain a stable physiological pH at 4°C and 37°C over a period of 4 weeks using sodium phosphate buffer it was found that the composition requires 10mM sodium phosphate. At this level, however, adsorption of Δ G287 was only 50% (Figure 1, lane 5). 100% adsorption could be maintained at 2.5mM sodium phosphate (Lanes 5 of Figures 2 & 3), but this composition does not have a stable pH at either 4°C or 37°C.

It was therefore necessary to find an alternative buffer system which would maintain pH stability without decreasing adsorption.

Adsorption was 95-100% using 5mM histidine (Lanes 6 of Figures 1, 2 & 3) and also using 10mM histidine (Figure 2, lane 7). In terms of adsorption, therefore, 5mM or 10mM histidine was equivalent to 2.5mM sodium phosphate in the presence of either 1mg/ml (Figures 1 & 2) or 3.3mg/ml (Figure 3) aluminium oxyhydroxide.

In order to define the pH range in which the vaccine compositions are stable, three starting pH values were chosen (pH 6.0, 6.5 and 7.0) and pH stability was monitored over four weeks in the presence of either 2.5mM sodium phosphate or 5mM histidine. Stability was monitored at both 4°C and 37°C.

The antigen in all vaccines was a combination of Δ G287 (100 μ g/ml) and OMV (50 μ g/ml) adjuvanted with 3.3mg/ml aluminium oxyhydroxide.

Figure 4 shows pH stability at 4°C and Figure 5 shows pH stability at 37°C [NB – due to bacterial contamination, no measurement of the pH 6.0 histidine-buffered vaccine was possible at 4 weeks].

At both temperatures the pH tended to increase over time with 2.5mM sodium phosphate buffer but was stable in the presence of 5mM histidine buffer.

In comparison with sodium phosphate buffer, therefore, the use of histidine offers pH stability over time without reducing adsorption.

Example 2 – adsorption of meningococcal C saccharide antigen

Saccharide conjugates tend to degrade by hydrolysis [7,8] when present in solution ('liquid' vaccines). Conjugates can be lyophilised to avoid this [7], but this requires adjuvant to be added at the point of reconstitution. It would be preferable to have a liquid form of the vaccine in which the saccharide is not subject to hydrolytic degradation.

-12-

This was investigated for a conjugate of meningococcus serogroup C oligosaccharide on CRM₁₉₇ carrier protein [20]. CRM₁₉₇ is acidic and thus does not completely adsorb to negatively charged aluminium phosphates. Histidine, however, is positively charged and it was thought that this might be able to mask the negative charge. Histidine buffer was thus tested with the aim of improving adsorption of MenC-CRM₁₉₇ to aluminium hydroxyphosphate.

Antigen adsorption was evaluated in the presence and absence of histidine buffer by measuring protein concentration in the vaccine supernatant using the BCA protein assay, after centrifugation to separate the adjuvant pellet. The vaccines were formulated as 20µg/ml oligosaccharide and 45µg/ml CRM₁₉₇ protein. Results were as follows:

Antigen	Adjuvant	[Histidine] (mM)	Protein (µg/ml)
MenC-CRM ₁₉₇	Hydroxyphosphate Al ³⁺ =0.6mg/ml	0	42.4
		5	28.6
		10	21.7

Antigen adsorption thus improves when histidine is present in the formulation: adsorption is about 6% in the absence of histidine; 5mM histidine increases this to 36%; 10mM histidine increases adsorption to almost 52%.

Histidine is thus a useful additive for improving the adsorption of antigens to aluminium hydroxyphosphate.

Example 3 – adsorption of meningococcal B NadA antigen

NadA (Neisserial adhesin A) from serogroup B *N.meningitidis* is disclosed as protein '961' in ref.11 (SEQ IDs 2943 & 2944) and as 'NMB1994' in ref.13 (see also GenBank accession numbers 11352904 & 7227256). Allelic forms of NadA are disclosed in reference 91. Preferred forms of NadA lack the C-terminus anchor domain ('961c').

961c (100µg/ml) was adsorbed onto aluminium oxyhydroxide (3mg/ml) in the presence of 10mM histidine buffer, pH 6.5. After 4 weeks of storage at either 2-8°C or at 36-38°C, the antigen remained 100% adsorbed (Figures 8 & 9, lane 6). The pH of the composition was 6.44 at time zero and after 4 weeks of storage rose very slightly to 6.48 (2-8°C) or 6.47 (36-38°C).

Example 4 – adsorption of meningococcal B hybrid antigens

References 92 & 93 disclose hybrid expression of meningococcal B antigens. One such hybrid is 'ΔG287_{nz}-953' and another is '936-741'. These two hybrids (100µg/ml) were each adsorbed onto aluminium oxyhydroxide (3mg/ml) in the presence of 10mM histidine buffer, pH 6.3. After 4 weeks of storage at either 2-8°C or at 36-38°C, 'ΔG287_{nz}-953' remained 100% adsorbed (Figures 6 & 7, lane 7), with pH rising slightly from 6.44 to 6.52 (2-8°C) or 6.53 (36-38°C). '936-741' remained 100% adsorbed at 36-38°C (Figure 9, lane 7) but was ~99% adsorbed at 2-8°C (Figure 8, lane 7), with pH rising slightly from 6.33 to 6.37 (2-8°C) or 6.38 (36-38°C).

Example 5 – adsorption of meningococcal OMVs

As mentioned above, OMV vaccines from meningococcus B are well known. OMVs were prepared from the Norwegian strain of meningococcus B or from a New Zealand strain (394/98). These two OMV preparations (50µg/ml) were adsorbed onto aluminium oxyhydroxide (3mg/ml) in the presence of 10mM histidine buffer, pH 6.5. After 4 weeks of storage at either 2-8°C or at 36-38°C, both OMV preparations remained 100% adsorbed (Figures 8 & 9, lanes 8 & 9). For the Norwegian OMVs, pH rose slightly from 6.39 to 6.42 over 4 weeks at both storage temperatures. For the New Zealand OMVs, pH rose slightly from 6.40 to 6.42 (2-8°C) or 6.43 (36-38°C).

New Zealand OMVs were alternatively formulated with 5mM histidine. Starting with pure water, the aluminium oxyhydroxide was added, followed by histidine, with 10 minutes mixing. The OMVs were then added and mixed for 15 minutes. NaCl was then added followed by 10 minutes further mixing. The final composition was 3.3mg/ml aluminium oxyhydroxide, 7.5mM NaCl, 5mM histidine, 100µg/ml OMV, pH 6.42.

During storage at either 2-8°C or 36-36°C, pH and OMV adsorption varied as follows:

	pH		% Adsorption	
	2-8°C	36-38°C	2-8°C	36-38°C
Time zero	6,42	6,42	100	100
15 days	6,36	6,37	100	100
30 days	6,35	6,34	100	100

A comparison of lanes 4 & 5 (2-8°C) or lanes 8 & 9 (36-38°C) in Figure 10 shows that OMVs remain adsorbed after 1 month of storage.

Example 6 – adsorption of mixtures of meningococcal OMVs and protein antigens

961c, ΔG287_{nz}-953 and 936-741 were mixed at 100µg/ml of each antigen and the mixture was adsorbed onto aluminium oxyhydroxide (3mg/ml) in the presence of 10mM histidine buffer, pH 6.3.

In two further formulations, OMVs were included (50µg/ml) from either Norwegian or New Zealand strain meningococcus B.

All antigens in the three mixtures (Figures 6 & 7, lanes 8-10) showed 100% adsorption after 4 weeks of storage at either 2-8°C or at 36-38°C, except for 936-741 which was ~96% adsorbed in all three mixtures at 2-8°C and ~99% adsorbed at 36-38°C. The pH of each of the three mixtures rose slightly from 6.53 at time zero to 6.62 after 4 weeks at 2-8°C. At 36-38°C, the pH of three mixtures rose to 6.71±0.02.

The individual antigens brought residual phosphate ions into the mixture from their own PBS. Phosphate ions were sometimes present at between 3 and 5 mM in the combined antigen mixture. In the presence of these high concentrations of residual phosphate buffer, it was difficult to stabilise pH within 6.0 to 7.0, even with 5mM histidine. When histidine was increased to 10mM, however, pH

-14-

was stabilised. Furthermore, the antigens remained adsorbed even after 1 month of storage at either 2-8°C or at 36-38°C.

Example 7 – adsorption of meningococcal A saccharide antigen

- 5 Reference 94 discloses CRM₁₉₇ conjugates of capsular oligosaccharide from serogroup A meningococcus. The conjugates are not fully stable and are therefore prepared in lyophilised form, ready for re-constitution at the time of administration. The lyophilised form was prepared to have components which give the following composition after reconstitution into a unit dose:

Component	Concentration
CRM-MenA	20µg saccharide/ml
Potassium phosphate buffer	5 mM
Mannitol	15 mg/ml

This composition has no adjuvant, so an adjuvant was prepared for its reconstitution:

Component	Concentration
Aluminium oxyhydroxide	0.68 mg Al ³⁺ /ml
Histidine buffer	10 mM
Sodium chloride	9 mg/ml
Tween 80	0.005%
PH	7.2±0.05

* amorphous hydroxyphosphate, PO₄/Al molar ratio between 0.84 and 0.92

10 **Example 8 – adsorption of meningococcal C, W135 and Y saccharide antigens**

Reference 94 discloses CRM₁₉₇ conjugates of capsular oligosaccharides from meningococcus serogroups C, W135 and Y. A trivalent mixture of the three conjugates either adsorbed onto an aluminium oxyhydroxide adjuvant (2mg/ml) or an aluminium hydroxyphosphate adjuvant (0.6mg/ml Al³⁺) was prepared. The compositions of the two trivalent mixtures were as follows:

Component	Concentration	Concentration
Aluminium oxyhydroxide	0.68 mg Al ³⁺ /ml	-
Aluminium hydroxyphosphate*	-	0.6mg Al ³⁺ /ml
CRM-MenC	20µg saccharide/ml	20µg saccharide/ml
CRM-MenY	20µg saccharide/ml	20µg saccharide/ml
CRM-MenW135	20µg saccharide/ml	20µg saccharide/ml
Sodium phosphate buffer	-	10 mM
Histidine buffer	10 mM	-
Sodium chloride	9 mg/ml	9 mg/ml
Tween 80	0.005%	0.005%

* amorphous hydroxyphosphate, PO₄/Al molar ratio between 0.84 and 0.92

-15-

For the oxyhydroxide/histidine formulation, stability of the saccharide components either in the bulk mixture or after packaging into vials was as follows:

Time (days)	Stored at 2-8°C		Stored at 36-38°C	
	Free saccharide (µg/ml)	Free saccharide %	Free saccharide (µg/ml)	Free saccharide %
MenC bulk				
0	<1.2	<6	<1.2	<6
15	<1.2	<6	<1.2	<6
30	<1.2	<6	<1.2	<6
MenC vials				
0	<1.2	<6	<1.2	<6
15	<1.2	<6	<1.2	<6
30	<1.2	<6	1.3	6.6
MenW135 bulk				
0	2.5	12.5	2.5	12.5
15	2.3	11.4	3.4	16.8
30	2.3	11.5	3.5	17.3
MenW135 vials				
0	2.1	10.6	2.1	10.6
15	2.3	11.7	2.7	13.3
30	20.	10.2	3.3	16.3
MenY bulk				
0	1.7	8.3	1.7	8.3
15	<1.3	<6.3	2.0	10.2
30	1.3	6.3	2.4	12.2
MenY vials				
0	1.4	7.1	1.4	7.1
15	1.5	7.6	2.1	10.7
30	1.3	6.3	2.9	14.3

Free saccharide levels are thus stable for at least 1 month at 2-8°C, before and after packaging.

Under thermal stress conditions, small increases in free saccharide are seen over time for MenW135 and MenY, but MenC remains stable.

Over the 30 days, pH in vials and bulk was stable at 7.15±0.05 at both storage temperatures.

Example 9 – adsorption of meningococcal A, C, W135 and Y saccharide antigens

The two trivalent liquid compositions of example 8 were diluted and 0.5ml used to reconstitute the lyophilised MenA conjugate of example 7. The resulting tetravalent mixture was administered to ten Balb/c mice (female 6-8 weeks old) per group by subcutaneous injection at day 0 and 28. The mixture contained 2µg of each saccharide conjugate per dose, which represents 1/5 of the single human dose (SHD). Controls were saline or unconjugated homologous polysaccharides. Bleedings were performed before immunization and then at day 42, with sera stored at -70°C.

-16-

All the conjugates used were safe and immunogenic in the animals. GMT post-II ELISA titres (with 95% confidence intervals) were as follows:

Vaccine	Adjuvant	A	Y	W135	C
MenA (lyophilised and resuspended)	Hydroxyphosphate	172 (69-439)	-	-	-
	Oxyhydroxide	619 (419-906)	-	-	-
MenY	Hydroxyphosphate	-	328 (147-731)	-	-
	Oxyhydroxide	-	452 (344-593)	-	-
MenW	Hydroxyphosphate	-	-	80 (28-225)	-
	Oxyhydroxide	-	-	277 (185-411)	-
MenC	Hydroxyphosphate	-	-	-	317 (152-659)
	Oxyhydroxide	-	-	-	723 (615-851)
MenA (lyophilized) + MenC, W135, Y	Hydroxyphosphate	32 (15-68)	397 (252-627)	99 (35-288)	114 (53-246)
	Oxyhydroxide	206 (112-372)	141 (97-205)	139 (76-251)	163 (122-218)

Typically, therefore, titres are higher in the aluminium oxyhydroxide + histidine groups. Serum bactericidal titres were also generally better in the aluminium oxyhydroxide + histidine groups.

- 5 In parallel experiments, mice were immunised as described above but the vaccine compositions contained different ratios of the various oligosaccharide conjugates. Lyophilised MenA oligo-conjugate was used in all experiments. ELISA titres were as follows:

Antigen quantity (µg/dose)				Aluminium adjuvant	GMT ELISA (95% confidence interval)			
A	C	W135	Y		A	C	W135	Y
4	2	2	2	Hydroxyphosphate	177 (107-291)	367 (263-510)	239 (135-424)	239 (184-311)
4	2	2	2	Oxyhydroxide	390 (313-486)	494 (345-706)	338 (266-430)	158 (96-260)
2	2	2	2	Hydroxyphosphate	132 (59-296)	582 (268-1155)	143 (75-272)	247 (152-400)
2	2	2	2	Oxyhydroxide	337 (239-476)	569 (462-679)	171 (117-251)	100 (59-169)

- 10 A second set of experiments was performed using a dosage of 2 µg/ml saccharide for MenA and MenC, half that dosage for MenY, and a quarter dosage for MenW135. ELISA titres were as follows:

-17-

Antigen quantity ($\mu\text{g}/\text{dose}$)				Aluminium adjuvant	GMT ELISA (95% confidence interval)			
A	C	W135	Y		A	C	W135	Y
2	2	2	2	Hydroxyphosphate	32 (15-68)	114 (53-246)	99 (35-288)	397 (252-627)
				Oxyhydroxide	206 (112-372)	163 (122-218)	139 (76-251)	141 (97-205)
2	2	1	0.5	Hydroxyphosphate	96 (49-187)	238 (101-561)	42 (20-89)	315 (114-867)
				Oxyhydroxide	293 (144-597)	267 (158-451)	83 (43-163)	244 (152-392)

At least for serogroups A, C and W135, therefore, the oxyhydroxide + histidine formulation generally gives better titres than hydroxyphosphate at these different antigen ratios.

It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

REFERENCES (the contents of which are hereby incorporated by reference)

- 1 – *Vaccine Design: subunit & adjuvant approach* (1995) Powell & Newman (ISBN: 030644867X)
- 2 – International patent application WO93/24148.
- 3 – International patent application WO97/00697.
- 4 – International patent application WO98/48525.
- 5 – Burrell *et al.* (2000) *Vaccine* 18:2188-2192.
- 6 – Burrell *et al.* (1999) *Vaccine* 17:2599-2603.
- 7 – Corbel (1996) *Dev Biol Stand* 87:113-124.
- 8 – Sturgess *et al.* (1999) *Vaccine* 17:1169-1178.
- 9 – International patent application WO99/24578.
- 10 – International patent application WO99/36544.
- 11 – International patent application WO99/57280.
- 12 – International patent application WO00/22430.
- 13 – Tettelin *et al.* (2000) *Science* 287:1809-1815.
- 14 – International patent application WO96/29412.
- 15 – Pizza *et al.* (2000) *Science* 287:1816-1820.
- 16 – International patent application WO01/52885..
- 17 – Bjune *et al.* (1991) *Lancet* 338(8775):1093-1096.
- 18 – Fukasawa *et al.* (1999) *Vaccine* 17:2951-2958.
- 19 – Rosenqvist *et al.* (1998) *Dev. Biol. Stand.* 92:323-333.
- 20 – Costantino *et al.* (1992) *Vaccine* 10:691-698.
- 21 – Costantino *et al.* (1999) *Vaccine* 17:1251-1263.
- 22 – Watson (2000) *Pediatr Infect Dis J* 19:331-332.
- 23 – Rubin (2000) *Pediatr Clin North Am* 47:269-285, v.
- 24 – Jedrzejewski (2001) *Microbiol Mol Biol Rev* 65:187-207.
- 25 – Gustafsson *et al.* (1996) *N. Engl. J. Med.* 334:349-355.
- 26 – Rappuoli *et al.* (1991) *TIBTECH* 9:232-238.
- 27 – *Vaccines* (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.
- 28 – Del Giudice *et al.* (1998) *Molecular Aspects of Medicine* 19:1-70.
- 29 – International patent application WO93/18150.
- 30 – International patent application WO99/53310.
- 31 – International patent application WO98/04702.
- 32 – International patent application WO02/02606.
- 33 – Kalman *et al.* (1999) *Nature Genetics* 21:385-389.
- 34 – Read *et al.* (2000) *Nucleic Acids Res* 28:1397-406.
- 35 – Shirai *et al.* (2000) *J. Infect. Dis.* 181(Suppl 3):S524-S527.

- 36 – International patent application WO99/27105.
- 37 – International patent application WO00/27994.
- 38 – International patent application WO00/37494.
- 39 – International patent application WO99/28475.
- 40 – Ross *et al.* (2001) *Vaccine* 19:4135-4142.
- 41 – McMichael (2000) *Vaccine* 19 Suppl 1:S101-107.
- 42 – Schuchat (1999) *Lancet* 353(9146):51-6.
- 43 – International patent application WO02/34771.
- 44 – Dale (1999) *Infect Dis Clin North Am* 13:227-43, viii.
- 45 – Ferretti *et al.* (2001) *PNAS USA* 98: 4658-4663.
- 46 – Kuroda *et al.* (2001) *Lancet* 357(9264):1225-1240; see also pages 1218-1219.
- 47 – *J Toxicol Clin Toxicol* (2001) 39:85-100.
- 48 – Demicheli *et al.* (1998) *Vaccine* 16:880-884.
- 49 – Stepanov *et al.* (1996) *J Biotechnol* 44:155-160.
- 50 – Bell (2000) *Pediatr Infect Dis J* 19:1187-1188.
- 51 – Iwarson (1995) *APMIS* 103:321-326.
- 52 – Gerlich *et al.* (1990) *Vaccine* 8 Suppl:S63-68 & 79-80.
- 53 – Hsu *et al.* (1999) *Clin Liver Dis* 3:901-915.
- 54 – Sutter *et al.* (2000) *Pediatr Clin North Am* 47:287-308.
- 55 – Zimmerman & Spann (1999) *Am Fam Physician* 59:113-118, 125-126.
- 56 – Dreesen (1997) *Vaccine* 15 Suppl:S2-6.
- 57 – *MMWR Morb Mortal Wkly Rep* 1998 Jan 16;47(1):12, 19.
- 58 – Ingram (2001) *Trends Neurosci* 24:305-307.
- 59 – Rosenberg (2001) *Nature* 411:380-384.
- 60 – Moingeon (2001) *Vaccine* 19:1305-1326.
- 61 – Ramsay *et al.* (2001) *Lancet* 357(9251):195-196.
- 62 – Lindberg (1999) *Vaccine* 17 Suppl 2:S28-36.
- 63 – Buttery & Moxon (2000) *J R Coll Physicians Lond* 34:163-168.
- 64 – Ahmad & Chapnick (1999) *Infect Dis Clin North Am* 13:113-133, vii.
- 65 – Goldblatt (1998) *J. Med. Microbiol.* 47:563-567.
- 66 – European patent 0 477 508.
- 67 – US patent 5,306,492.
- 68 – International patent application WO98/42721.
- 69 – *Conjugate Vaccines* (eds. Cruse *et al.*) ISBN 3805549326, particularly vol. 10:48-114.
- 70 – Hermanson (1996) *Bioconjugate Techniques* ISBN: 0123423368 or 012342335X.

- 71 – European patent application 0372501.
- 72 – European patent application 0378881.
- 73 – European patent application 0427347.
- 74 – International patent application WO93/17712.
- 75 – International patent application WO98/58668.
- 76 – European patent application 0471177.
- 77 – International patent application WO00/56360.
- 78 – International patent application WO00/61761.
- 79 – Robinson & Torres (1997) *Seminars in Immunology* 9:271-283.
- 80 – Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648.
- 81 – Scott-Taylor & Dalgleish (2000) *Expert Opin Investig Drugs* 9:471-480.
- 82 – Apostolopoulos & Plebanski (2000) *Curr Opin Mol Ther* 2:441-447.
- 83 – Ilan (1999) *Curr Opin Mol Ther* 1:116-120.
- 84 – Dubensky *et al.* (2000) *Mol Med* 6:723-732.
- 85 – Robinson & Pertmer (2000) *Adv Virus Res* 55:1-74.
- 86 – Donnelly *et al.* (2000) *Am J Respir Crit Care Med* 162(4 Pt 2):S190-193.
- 87 – Davis (1999) *Mt Sinai J Med* 66:84-90.
- 88 – Gennaro (2000) *Remington: The Science and Practice of Pharmacy*. 20th edition, ISBN: 0683306472.
- 89 – WO93/13202.
- 90 – International patent application WO01/64922.
- 91 – International patent application filed 26 July 2002 under attorney reference P027797WO in the name of CHIRON SpA claiming priority from UK patent applications 0118401.9, 0121591.2 and 0211025.2.
- 92 – International patent application WO01/64920.
- 93 – UK patent application 0121591.2.
- 94 – International patent application filed 20 June 2002 under attorney reference P027504WO in the name of CHIRON SpA claiming priority from UK patent application 0115176.0.

CLAIMS

1. A composition comprising an antigen, an aluminium salt and histidine.
2. The composition of claim 1, wherein the antigen is a protein antigen or a saccharide antigen.
3. The composition of claim 1 or claim 2, wherein the antigen is a bacterial antigen selected from
5 the group consisting of:
 - a protein antigen from *N.meningitidis*;
 - an outer-membrane vesicle (OMV) preparation from *N.meningitidis*;
 - a saccharide antigen from *N.meningitidis*;
 - a saccharide antigen from *Streptococcus pneumoniae*;
 - 10 – an antigen from *Bordetella pertussis*;
 - a diphtheria antigen;
 - a tetanus antigen;
 - a protein antigen from *Helicobacter pylori*;
 - a saccharide antigen from *Haemophilus influenzae*;
 - 15 – an antigen from *N.gonorrhoeae*;
 - an antigen from *Chlamydia pneumoniae*;
 - an antigen from *Chlamydia trachomatis*;
 - an antigen from *Porphyromonas gingivalis*;
 - an antigen from *Moraxella catarrhalis*;
 - 20 – an antigen from *Streptococcus agalactiae*;
 - an antigen from *Streptococcus pyogenes*; and
 - an antigen from *Staphylococcus aureus*.
4. The composition of claim 3, wherein the antigen is from *Neisseria meningitidis* serogroup B.
5. The composition of claim 2 or claim 3, wherein the saccharide antigen is a conjugated
25 oligosaccharide antigen.
6. The composition of any preceding claim, wherein a protein antigen is replaced by nucleic acid encoding the protein.
7. The composition of any preceding claim, wherein the antigen is adsorbed to the aluminium salt.
8. The composition of any preceding claim, wherein the aluminium salt is a hydroxide (*e.g.* oxyhydroxide) or a phosphate (*e.g.* hydroxyphosphate), or a mixture of two or more of said salts.
30
9. The composition of any preceding claim, wherein aluminium salt is aluminium hydroxyphosphate and the antigen is an acidic antigen.
10. The composition of any preceding claim, wherein the concentration of histidine in the composition is between 1mM and 100mM.

-22-

11. The composition of claim 10, wherein the concentration of histidine is between about 5mM and about 10mM.
12. The composition of any preceding claim, further comprising a sodium salt (*e.g.* sodium phosphate).
- 5 13. The composition of claim 12, wherein the concentration of the sodium salt is between about 2.5mM and about 5mM.
14. The composition of any preceding claim, wherein the pH of the composition is between 6 and 7.
15. The composition of any preceding claim, further comprising a pharmaceutically acceptable carrier.
- 10 16. The composition of any preceding claim, comprising more than one antigen.
17. The composition of claim 16, wherein more than one of the antigens is adsorbed to an aluminium salt.
18. The composition of claim 16 or claim 17, comprising 2, 3, 4, 5, 6 or 7 of the following: an antigen from *Bordetella pertussis*; a diphtheria antigen; a tetanus antigen; an antigen from hepatitis B virus; a saccharide antigen from *Haemophilus influenzae*; inactivated polio virus; and
15 a saccharide antigen from *N.meningitidis* serogroup C.
19. The composition of any preceding claim for use as a medicament.
20. The composition of claim 19, wherein the medicament is a vaccine.
21. The use of the composition of any one of claims 1 to 18 in the manufacture of a medicament for
20 raising an immune response in a mammal against the antigen(s).
22. The use of claim 21, wherein the medicament is a vaccine.
23. A method for raising an immune response in a mammal comprising the step of administering an effective amount of the composition of any one of claims 1 to 18.
24. The method of claim 23, wherein the mammal is a human.
- 25 25. A process for producing the composition of any one of claims 1 to 18, comprising the step of admixing one or more antigens, an aluminium salt and histidine.
26. The process of claim 25, wherein the admixing comprises: a first step of admixing (i) the aluminium salt and (ii) histidine, to give a histidine/aluminium salt admixture; and a second step of admixing (i) said histidine/aluminium salt admixture and (ii) one or more antigens.
- 30 27. The process of claim 26, wherein the composition is combined with an antigenic composition.

1/4

FIGURE 1





FIGURE 2



2/4

FIGURE 3




FIGURE 4










FIGURE 5



3/4

FIGURE 6**FIGURE 7****FIGURE 8**

4/4

FIGURE 9**FIGURE 10**

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/IB 02/03495

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K39/39 A61P31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 57906 A (MERCK) 5 October 2000 (2000-10-05) page 18 -page 22 ---	1-27
Y	WO 01 41800 A (CHIRON CORPORATION) 14 June 2001 (2001-06-14) page 20 -page 22 ---	1-27
Y	WO 99 48525 A (SMITHKLINE BEECHAM BIOLOGICALS) 30 September 1999 (1999-09-30) page 24 -page 28 ---	1-27
A	EP 0 835 663 A (SMITHKLINE BEECHAM BIOLOGICALS) 15 April 1998 (1998-04-15) the whole document --- -/--	1-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

13 January 2003

Date of mailing of the international search report

17/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

Interna Application No

PCT/IB 02/03495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HO M M ET AL: "Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 7-8, 22 November 2000 (2000-11-22), pages 716-725, XP004225388 ISSN: 0264-410X the whole document -----</p>	1-27

INTERNATIONAL SEARCH REPORT

Int: al application No.
PCT/IB 02/03495

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 23-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/IB 02/03495

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0057906	A	05-10-2000	US 6245568 B1	12-06-2001
			AU 3909300 A	16-10-2000
			EP 1165126 A1	02-01-2002
			WO 0057906 A1	05-10-2000
			US 2001021385 A1	13-09-2001
WO 0141800	A	14-06-2001	EP 1233784 A2	28-08-2002
			WO 0141800 A2	14-06-2001
WO 9948525	A	30-09-1999	AU 735619 B2	12-07-2001
			AU 3417299 A	18-10-1999
			BR 9909037 A	05-12-2000
			CA 2325436 A1	30-09-1999
			CN 1295481 T	16-05-2001
			CZ 20003536 A3	15-08-2001
			WO 9948525 A1	30-09-1999
			EP 1066053 A1	10-01-2001
			HU 0101323 A2	28-08-2001
			JP 2002507581 T	12-03-2002
			NO 20004758 A	08-11-2000
			PL 343065 A1	30-07-2001
			TR 200002737 T2	21-12-2000
EP 835663	A	15-04-1998	EP 0835663 A2	15-04-1998
			AP 567 A	25-11-1996
			AT 168271 T	15-08-1998
			AU 709406 B2	26-08-1999
			AU 1648097 A	29-05-1997
			AU 4315693 A	30-12-1993
			CA 2136429 A1	09-12-1993
			CN 1085450 A	20-04-1994
			CZ 9402892 A3	13-09-1995
			DE 69319728 D1	20-08-1998
			DE 69319728 T2	04-02-1999
			DK 642355 T3	30-11-1998
			WO 9324148 A1	09-12-1993
			EP 0642355 A1	15-03-1995
			ES 2118963 T3	01-10-1998
			FI 945483 A	20-01-1995
			HK 1011290 A1	28-04-2000
			HU 71791 A2	28-02-1996
			IL 105770 A	16-08-1998
			JP 7508267 T	14-09-1995
			MX 9302982 A1	01-12-1993
			NO 944475 A	18-01-1995
			NZ 253065 A	28-10-1996
			PL 174077 B1	30-06-1998
			RU 2160120 C2	10-12-2000
			SG 48365 A1	17-04-1998
			SI 9300271 A	31-12-1993
			SK 142194 A3	09-08-1995
			US 6013264 A	11-01-2000
			ZA 9303541 A	21-06-1994